Get the Stockscreener App
4.365
3.53%
-0.145
Sellas Life Sciences Group Inc stock is traded at $4.365, with a volume of 2.12M.
It is down -3.53% in the last 24 hours and up +57.07% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$4.51
Open:
$4.52
24h Volume:
2.12M
Relative Volume:
0.27
Market Cap:
$743.28M
Revenue:
-
Net Income/Loss:
$-37.34M
P/E Ratio:
-3.2096
EPS:
-1.36
Net Cash Flow:
$-36.91M
1W Performance:
+9.32%
1M Performance:
+57.07%
6M Performance:
+136.46%
1Y Performance:
+339.96%
1-Day Range:
$4.32
$4.53
1-Week Range:
$3.80
$4.84
52-Week Range:
$0.9516
$5.1765
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
4.365 | 767.97M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
Heightened Volatility Marks Sellas Life Sciences as Key Clinical Milestones Approach - AD HOC NEWS
Best Penny Stocks To Follow TodayJanuary 4th - MarketBeat
Sellas Life Sciences Rises as Traders Weigh REGAL Debate and Microcap Volatility - StocksToTrade
Why I’m Selling Sellas Life Sciences Ahead Of The REGAL Reveal (NASDAQ:SLS) - Seeking Alpha
Will SELLAS Life Sciences Group Inc. stock see PE expansion2025 Pullback Review & Proven Capital Preservation Methods - bollywoodhelpline.com
Sellas Life Sciences Shares Surge with Strategic Clinical Study Moves - StocksToTrade
SELLAS Life Sciences’ European Partnership Spurs Market Optimism - timothysykes.com
Key Developments in SLS’s Market Strategy - StocksToTrade
SELLAS Life Sciences Rallies After Major Trial Developments - timothysykes.com
A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Collaboration - simplywall.st
Sellas Life Sciences Stock Dips as Volatility Returns After Recent Headlines - StocksToTrade
Sellas Life Sciences Expands SLS009 Program Into Europe With IMPACT-AML Agreement - StocksToTrade
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 5.5%Should You Sell? - MarketBeat
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe - Sahm
SELLAS partners with IMPACT-AML for European SLS009 trials By Investing.com - Investing.com Nigeria
A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement - Yahoo Finance
How SELLAS’s IMPACT-AML Trial Expansion At SELLAS Life Sciences Group (SLS) Has Changed Its Investment Story - simplywall.st
SLS Stock In Spotlight On EU Expansion For Cancer Therapy – Retail Says Potential Catalyst For Buyout - Asianet Newsable
SELLAS partners with IMPACT-AML for European SLS009 trials - Investing.com
Aug Fed Impact: Is CACC trading at a discountVolume Spike & Fast Moving Stock Trade Plans - baoquankhu1.vn
SELLAS Life Sciences Group Stock (SLS) Opinions on Phase 3 REGAL Trial Progress - Quiver Quantitative
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 10.3%Here's What Happened - MarketBeat
Sellas Life Sciences Jumps in Volatile Session After Recent Selloff - StocksToTrade
Promising Penny Stocks To Add to Your WatchlistJanuary 1st - MarketBeat
Sellas Life Sciences Rebounds After Volatile Selloff - timothysykes.com
Sellas Life Sciences Stock Slides as Trading Dynamics Overshadow Trial Timeline Update - StocksToTrade
Published on: 2026-01-10 22:25:31 - Улправда
SELLAS Stock Dips Amid Volatility After Warrant Exercise Update - StocksToTrade
Sellas Life Sciences falls for fourth straight session — what’s driving the sell-off? - MSN
SELLAS Life Sciences falls for fourth straight session — what’s driving the sell-off? - MSN
SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off? - Asianet Newsable
SLS Stock Slides Amid Volatility as Traders Focus on Dilution Concerns - timothysykes.com
SELLAS Life Sciences Falls For Fourth Straight SessionWhat's Driving The Sell Off? - Menafn
Published on: 2026-01-08 22:04:52 - Улправда
Is SELLAS Life Sciences Group Inc. stock a top pick in earnings seasonJuly 2025 Catalysts & Expert-Curated Trade Recommendations - Улправда
Published on: 2026-01-09 05:48:17 - Улправда
Why SELLAS Life Sciences Group Inc. stock could outperform in 2025July 2025 Breakouts & AI Powered Buy/Sell Recommendations - Улправда
Investment Review: Why global investors buy SELLAS Life Sciences Group Inc. (RXK3) stock2025 Valuation Update & Scalable Portfolio Growth Ideas - ulpravda.ru
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - GlobeNewswire
SELLAS Life Sciences Group stock soars as it nears final analysis in cancer study - MSN
Dip Buying: How interest rate cuts could boost SELLAS Life Sciences Group Inc. stockJuly 2025 Earnings & AI Optimized Trading Strategy Guides - ulpravda.ru
SELLAS Raises $26.5 Million Through Warrant Exercises - TipRanks
SLS Stock Breaches $5 Level After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B - Asianet Newsable
Penny Stocks To Follow TodayJanuary 3rd - MarketBeat
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 8.4%Here's Why - MarketBeat
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):